Cover Image
市場調查報告書

MediPoint:神經血管介入 - 美國市場的分析與預測

MediPoint: Neurovascular Interventions - US Analysis and Market Forecasts

出版商 GlobalData 商品編碼 301166
出版日期 內容資訊 英文 324 Pages
訂單完成後即時交付
價格
Back to Top
MediPoint:神經血管介入 - 美國市場的分析與預測 MediPoint: Neurovascular Interventions - US Analysis and Market Forecasts
出版日期: 2014年04月30日 內容資訊: 英文 324 Pages
簡介

全球神經血管介入正以2位數的大幅速度在急速成長。由於神經介入技術與低侵入性治療技術急速進步,未來可治療的疾病也在日益增加。神經血管介入市場分為血管堵塞、血管再生、機械除去血栓、進入/支援等四個領域。 今後到2020年間,受到疾病得病率上升及保險公司降低成本的影響,預測美國市場將達到7億200萬美金的規模。

本報告提供美國腦血管疾病(顱內動脈瘤/動靜脈畸形,動脈粥狀硬化等)治療用神經血管介入市場相關分析,彙整疾病概要和市場結構,目前未滿足需求,主要的推動及阻礙市場要素,今後的市場機會,現在臨床實驗中的主要產品,市場趨勢(過去3年的實際成果值和今後7年的預測值),各類型產品的詳細趨勢,再加上主要企業簡介等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

第3章 臨床結果

  • 疾病的管理
    • 顱內動脈瘤
    • 顱內動靜脈畸形
    • 硬薄膜動靜脈瘺
    • 顱內/顱外動脈粥狀硬化
    • 中風
  • 治療方式
    • 概要
    • 醫藥/化療
    • 外科療法
    • 血管內療法

第4章 產業概要

  • 概況
  • 治療的趨勢
    • 顱內動脈瘤
    • 顱內動靜脈畸形
    • 動脈粥狀硬化
    • 急性缺血性中風
  • 市場進入
    • 法規的流程
    • 醫生的認識·決策流程
    • 臨床診療的變化
    • 臨床資料的不足
    • 成本的考慮
    • 醫療費給付的趨勢
  • 法規的問題/回收
    • 產品的回收
  • 企業合併·收購(M&A)/主要的夥伴關係
  • 經濟上的影響
    • 顱內動脈瘤/動靜脈畸形的情況
    • 中風的情況
  • 第5章 未滿足需求
  • 概要
  • 訓練、實績、醫師訓練指南的需求
  • 臨床資料的不足
  • 改善急性缺血性中風的管理
  • 處理複雜化外科療法
  • 手術夾的問題
  • 欠缺處理未破裂顱內動脈瘤治療策略
  • 複雜形態、規模的動脈瘤有效治療法
  • 顱內動靜脈畸形的治療困難
  • 處理球囊血管新生法相關課題
  • 處理神經血管用支撐術相關課題
  • 雙重抗血小板療法(DAPT)的複雜化
  • 改善醫藥療法的需求
  • 緩和就醫需求

第6章 市場機會分析

  • 神經血管介入市場
  • 改善介入神經放射學設備的設計
  • 複雜的顱內動脈瘤/動靜脈畸形的治療相關課題
  • 以多數患者為對象的治療方法
  • 急性缺血性中風患者治療方法的最佳化
  • 開發藥物釋放型設備
  • 新興市場

第7章 推動市場要素與課題

  • 推動市場要素
    • 疾病得病率的上升
    • 改善血管內栓塞臨床結果
    • 改變血管支架/球囊輔助栓塞的治療法
    • 可行的複雜顱內動脈瘤治療選擇
    • 治療動脈瘤用線圈以外的替代性的閉塞形成設備
    • 顱內動靜脈畸形的血管內閉塞
    • 治療顱內動靜脈畸形的影像診斷
    • 頸動脈硬化性疾病的支架
    • 小型支架設備
    • 改善機械除血栓設備的最大通率
    • 成本控制
    • 得到長期性、具成本效率資料的可能性
  • 市場課題
    • 介入神經放射學治療·設備的複雜性
    • 臨床資料的不足
    • 高治療費
    • 醫療費給付額的不足
    • 缺乏生物活性/塗層線圈的優勢
    • 中風治療的替代性方法
    • 法規上的問題:美國FDA和EC標示
    • 降低醫療費的動向與醫療費給付
    • 可用的風險投資
    • 醫療設備的貨品稅

第8章 競爭力的評估

  • 概要
  • 美國市場佔有率
  • 已上市產品(計29產品)

第9章 開發中產品的評估

  • 概要
  • 各開發階段的開發中產品
  • 產品簡介(計12產品)

第10章 臨床實驗分析

  • 概要
  • 值得注意的臨床實驗
    • 血管閉塞
    • 血流重建
    • 血管再生
    • 機械除血栓

第11章 現在·未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介(計30公司份)

第12章 美國市場的未來展望

  • 概要
  • 市場分析
    • 血管閉塞
    • 血管再生
    • 機械除血栓設備市場
    • 連結設備

第13章 附錄

圖表一覽

目錄
Product Code: GDME1096CFR

The global neurovascular interventions market is a vast, double-digit market that consists of innovative and emerging technologies. Rapid advances in the field of neurovascular interventions and development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. The neurovascular interventions market consists of four device segments including embolization, revascularization, mechanicalthrombectomy and access/support devices.

GlobalData expects the neurovascular interventions market in the US to reach $702m by 2020, increasing slowly throughout the forecast period. The neurovascular interventions market will be driven by: the rising prevalence of cerebrovascular disease; the cost savings incurred by government agencies, such as Medicare, and private health insurance companies; and the adoption of innovative technologies such as flow diverters and stent retrievers.

Scope

  • An overview of Neurovascular, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized the US Neurovascular market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
  • Investigation of current and future market competition for Neurovascular.
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the Neurovascular sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

  • Understand the trends shaping and driving the US Neurovascular market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in the US Neurovascular market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What's the next big thing in the US Neurovascular market landscape? Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst

3. Clinical Outcomes

  • 3.1. Disease Management
    • 3.1.1. Intracranial Aneurysms
    • 3.1.2. Intracranial Arteriovenous Malformations
    • 3.1.3. Dural Arteriovenous Fistulas
    • 3.1.4. Intracranial and Extracranial Atherosclerotic Disease
    • 3.1.5. Stroke
  • 3.2. Treatment Modalities
    • 3.2.1. Overview
    • 3.2.2. Medical/Chemical Therapy
    • 3.2.3. Surgical Therapy
    • 3.2.4. Endovascular Therapy

4. Industry Overview

  • 4.1. Overview
  • 4.2. Procedure Trends
    • 4.2.1. Intracranial Aneurysms
    • 4.2.2. Intracranial Arteriovenous Malformations
    • 4.2.3. Atherosclerotic Disease
    • 4.2.4. Acute Ischemic Stroke
  • 4.3. Market Access
    • 4.3.1. Regulatory Process
    • 4.3.2. Physician Perception and Decision Making Process
    • 4.3.3. Variations in Clinical Practice
    • 4.3.4. Lack of Clinical Data
    • 4.3.5. Cost-Considerations
    • 4.3.6. Reimbursement Trends
  • 4.4. Regulatory Issues/Recalls
    • 4.4.1. Product Recalls
  • 4.5. Mergers and Acquisitions/Key Partnerships
    • 4.5.1. Covidien and Nfocus Neuromedical
    • 4.5.2. Stryker Corporation and Surpass Medical
    • 4.5.3. Covidien and MindFrame
    • 4.5.4. Covidien and Reverse Medical Corporation
    • 4.5.5. Stryker Corporation and Boston Scientific Neurovascular
    • 4.5.6. Stryker Corporation and Concentric Medical
    • 4.5.7. Covidien and ev3
    • 4.5.8. Medtronic and Invatec
    • 4.5.9. Johnson & Johnson and Micrus Endovascular
    • 4.5.10. ev3and Chestnut Medical Technologies
    • 4.5.11. Boston Scientific Corporation and Guidant Corporation
  • 4.6. Economic Impact
    • 4.6.1. Economic Impact of Intracranial Aneurysms and Arteriovenous Malformations
    • 4.6.2. Economic Impact of Stroke
    • 4.6.3. Treatment Costs of Cerebrovascular Disease

5. Unmet Needs

  • 5.1. Overview
  • 5.2. Need for Practice, Performance, and Physician Training Guidelines
  • 5.3. Lack of Clinical Data
  • 5.4. Improve Management of Acute Ischemic Stroke
  • 5.5. Address Complications of Surgical Therapy
  • 5.6. Addressing the Challenges of Surgical Clipping
  • 5.7. Lack of Optimal Treatment Strategy for Unruptured Intracranial Aneurysms
  • 5.8. Need for Effective Therapies for Complex Aneurysm Morphologies and Sizes
  • 5.9. Difficulty in Treating Intracranial Arteriovenous Malformations
  • 5.10. Eliminating Mechanisms of Failure with Balloon Angioplasty
  • 5.11. Addressing Challenges of Neurovascular Stenting
    • 5.11.1. Risk of Post-Procedural Complications
    • 5.11.2. In-Stent Restenosis
    • 5.11.3. Stent Navigation
  • 5.12. Complications of Dual Antiplatelet Therapy
  • 5.13. Need to Improve Medical Therapy
  • 5.14. Improve Ease of Access

6. Market Opportunity Analysis

  • 6.1. Neurovascular Interventions Market
  • 6.2. Improve Neurointerventional Device Design
  • 6.3. Challenges in Treating Complex Intracranial Aneurysms and Arteriovenous Malformations
    • 6.3.1. Intracranial Aneurysms
    • 6.3.2. Intracranial Arteriovenous Malformations
  • 6.4. Target Challenging Patient Populations
  • 6.5. Optimize Care for Acute Ischemic Stroke Patients
  • 6.6. Development of Drug-Eluting Devices
  • 6.7. Emerging Markets

7. Market Drivers and Barriers

  • 7.1. Market Drivers
    • 7.1.1. Rising Prevalence of Disease
    • 7.1.2. Improved Clinical Outcomes with Endovascular Coiling
    • 7.1.3. Remodeling Techniques with Stent and Balloon-Assisted Coiling
    • 7.1.4. Viable Therapeutic Option for Challenging/Complex Intracranial Aneurysms
    • 7.1.5. Alternative Non-Coiling Embolization Devices for Aneurysm Treatment
    • 7.1.6. Endovascular Embolization of Intracranial Arteriovenous Malformations
    • 7.1.7. Imaging Assessment for Intracranial Arteriovenous Malformation Treatment
    • 7.1.8. Stenting for Carotid Atherosclerotic Disease
    • 7.1.9. Low-Profile Stent Systems
    • 7.1.10. Improved Recanalization Rates with Mechanical Thrombectomy Devices
    • 7.1.11. Cost Savings
    • 7.1.12. Availability of Long-Term and Cost-Effective Data
  • 7.2. Market Barriers
    • 7.2.1. Complications of Neurointerventional Procedures and Devices
    • 7.2.2. Lack of Clinical Data
    • 7.2.3. High Cost of Treatment
    • 7.2.4. Lack of Reimbursement
    • 7.2.5. Lack of Superiority of Bioactive/Coated Coils
    • 7.2.6. Alternative Technologies for Stroke Therapy
    • 7.2.7. Regulatory Challenges: US Food and Drug Administration and European Conformity Mark
    • 7.2.8. Healthcare Cost-Cutting and Reimbursement
    • 7.2.9. Availability of Venture Capital
    • 7.2.10. Medical Device Excise Tax

8. Competitive Assessment

  • 8.1. Overview
  • 8.2. US Market Share
  • 8.3. Marketed Products
    • 8.3.1. Aachen Resonance
    • 8.3.2. Abbott Vascular
    • 8.3.3. Acandis
    • 8.3.4. B. Braun
    • 8.3.5. BALT Extrusion
    • 8.3.6. Blockade Medical
    • 8.3.7. Boston Scientific Corporation
    • 8.3.8. Contego Medical
    • 8.3.9. Cook Medical
    • 8.3.10. Covidien
    • 8.3.11. Gardia Medical
    • 8.3.12. Gore Medical
    • 8.3.13. InspireMD
    • 8.3.14. ITGI Medical
    • 8.3.15. Johnson & Johnson
    • 8.3.16. Medikit
    • 8.3.17. Medtronic
    • 8.3.18. Merlin MD
    • 8.3.19. MicroPort Scientific Corporation
    • 8.3.20. Minvasys
    • 8.3.21. Neuravi
    • 8.3.22. Optimed
    • 8.3.23. Penumbra
    • 8.3.24. Phenox GmbH
    • 8.3.25. Reverse Medical
    • 8.3.26. Sequent Medical
    • 8.3.27. Stryker Neurovascular Intervention
    • 8.3.28. Terumo Corporation
    • 8.3.29. Valor Medical

9. Pipeline Assessment

  • 9.1. Overview
  • 9.2. Pipeline by Stage of Development
  • 9.3. Product Profiles
    • 9.3.1. Aneurysm Occlusion Saddle
    • 9.3.2. Ballstent Microcatheter
    • 9.3.3. Blood Clot Removing Device
    • 9.3.4. EKOS' EkoSonic Small Vessel Endovascular System
    • 9.3.5. Flow-Diverting Thin-Film Nitinol Covered Stent
    • 9.3.6. Ischemic Stroke System
    • 9.3.7. Janjua Aneurysm Net
    • 9.3.8. Multilayer Aneurysm Repair System
    • 9.3.9. NAVIMAX
    • 9.3.10. Palmaz Scientific Stents
    • 9.3.11. Silk Road System
    • 9.3.12. Transcranial Thrombectomy Catheter

10. Clinical Trial Analysis

  • 10.1. Overview
  • 10.2. Clinical Trials to Watch
    • 10.2.1. Embolization
    • 10.2.2. Flow Diversion
    • 10.2.3. Revascularization
    • 10.2.4. Mechanical Thrombectomy

11. Current and Future Players

  • 11.1. Overview
  • 11.2. Trends in Corporate Strategy
  • 11.3. Company Profiles
    • 11.3.1. BALT Extrusion
    • 11.3.2. Covidien
    • 11.3.3. Johnson & Johnson
    • 11.3.4. Penumbra
    • 11.3.5. Stryker Corporation
    • 11.3.6. Terumo Corporation
    • 11.3.7. Abbott Vascular
    • 11.3.8. Boston Scientific Corporation
    • 11.3.9. Cook Medical
    • 11.3.10. Gore Medical
    • 11.3.11. Medtronic
    • 11.3.12. Aachen Resonance
    • 11.3.13. Acandis
    • 11.3.14. B. Braun
    • 11.3.15. Blockade Medical
    • 11.3.16. Contego Medical
    • 11.3.17. Gardia Medical
    • 11.3.18. InspireMD
    • 11.3.19. ITGI Medical
    • 11.3.20. Medikit
    • 11.3.21. Merlin MD
    • 11.3.22. MicroPort Scientific Corporation
    • 11.3.23. Minvasys
    • 11.3.24. Neuravi
    • 11.3.25. Optimed
    • 11.3.26. Phenox GmBH
    • 11.3.27. Reverse Medical
    • 11.3.28. Sequent Medical
    • 11.3.29. Valor Medical
    • 11.3.30. Other Companies

12. US Market Outlook

  • 12.1. Overview
  • 12.2. Market Analysis
    • 12.2.1. Embolization Market
    • 12.2.2. Revascularization Market
    • 12.2.3. Mechanical Thrombectomy Market
    • 12.2.4. Access Device Market

13. Appendix

  • 13.1. Bibliography
  • 13.2. Abbreviations
  • 13.3. Report Methodology
    • 13.3.1. Overview
    • 13.3.2. Coverage
    • 13.3.3. Secondary Research
  • 13.4. Physicians and Specialists Included in this Study
    • 13.4.1. Vivek Gupta, MD
    • 13.4.2. Zsolt Kulscar, MD, PhD
    • 13.4.3. Salvatore Mangiafico, MD
    • 13.4.4. Thanh Nguyen, MD, FRCPc
    • 13.4.5. Eduardo Wajnberg, MD
    • 13.4.6. Phil White, MD
    • 13.4.7. Osama O Zaidat, MD, MS, FAAN, FAHA
  • 13.5. Primary Research
    • 13.5.1. Primary Research - Key Opinion Leader Interviews
    • 13.5.2. Expert Panel Validation
  • 13.6. Forecasting Methodology
  • 13.7. About the Authors
    • 13.7.1. Analysts
    • 13.7.2. Global Head of Healthcare
  • 13.8. About MediPoint
  • 13.9. About GlobalData
  • 13.10. Disclaimer

List of Tables

  • Table 1: Complications of Cerebral Artery Bypass Surgery
  • Table 2: Types of Cerebral Embolic Protection Devices
  • Table 3: Medicare National Average of Inpatient Hospital Payment for Neurovascular Interventions, 2013-2014
  • Table 4: US Mean Hospital Costs* for Treating Cerebrovascular Disease, 2011-2020 ($US)
  • Table 5: Aachen Resonance Neurovascular Intervention Marketed Product
  • Table 6: Aachen Resonance Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 7: Abbott Vascular Neurovascular Intervention Marketed Products
  • Table 8: Abbott Vascular Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 9: Acandis Neurovascular Intervention Marketed Products
  • Table 10: Acandis Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 11: B. Braun Neurovascular Intervention Marketed Product
  • Table 12: B. Braun Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 13: BALT Extrusion Neurovascular Intervention Marketed Products
  • Table 14: BALT Extrusion Neurovascular Intervention Marketed Access Products
  • Table 15: BALT Extrusion Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 16: Blockade Medical Neurovascular Intervention Marketed Product
  • Table 17: Blockade Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 18: Boston Scientific Neurovascular Intervention Marketed Products
  • Table 19: Boston Scientific Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 20: Contego Medical Neurovascular Intervention Marketed Product
  • Table 21: Contego Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 22: Cook Medical Neurovascular Intervention Marketed Products
  • Table 23: Cook Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 24: Covidien Neurovascular Interventional Marketed Products
  • Table 25: Covidien Neurovascular Intervention Marketed Access Products
  • Table 26: Covidien Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 27: Gardia Medical Neurovascular Intervention Marketed Product
  • Table 28: Gardia Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 29: Gore Medical Neurovascular Intervention Marketed Products
  • Table 30: Gore Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 31: InspireMD Neurovascular Intervention Marketed Product
  • Table 32: InspireMD Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 33: ITGI Medical Neurovascular Intervention Marketed Product
  • Table 34: ITGI Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 35: Codman Neurovascular Marketed Embolization Products
  • Table 36: Codman Neurovascular Marketed Mechanical Thrombectomy and Access Products
  • Table 37: Codman Neurovascular's (Codman & Shurtleff) Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 38: Cordis Corporation Marketed Neurointerventional Products
  • Table 39: Cordis Corporation Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 40: Medikit Neurovascular Intervention Marketed Products
  • Table 41: Medikit Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 42: Medtronic Neurovascular Intervention Marketed Products
  • Table 43: Medtronic Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 44: Merlin MD Neurovascular Intervention Marketed Product
  • Table 45: Merlin MD Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 46: MicroPort Scientific Corporation Neurovascular Intervention Marketed Products
  • Table 47: MicroPort Scientific Corporation Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 48: Minvasys Neurovascular Intervention Marketed Product
  • Table 49: Minvasys Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 50: Neuravi Neurovascular Intervention Marketed Product
  • Table 51: Neuravi Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 52: Optimed Neurovascular Intervention Marketed Products
  • Table 53: Optimed Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 54: Penumbra Neurovascular Intervention Marketed Products
  • Table 55: Penumbra Marketed Neurovascular Access Products
  • Table 56: Penumbra Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 57: Phenox GmbH Neurovascular Intervention Marketed Products
  • Table 58: Phenox GmbH Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 59: Reverse Medical Neurovascular Intervention Marketed Products
  • Table 60: Reverse Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 61: Sequent Medical Neurovascular Intervention Marketed Products
  • Table 62: Sequent Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 63: Stryker Neurovascular Intervention Marketed Products
  • Table 64: Stryker Neurovascular Intervention Marketed Mechanical Thrombectomy and Access Products
  • Table 65: Stryker Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 66: Terumo Europe N.V. and Terumo Interventional Systems Marketed Neurointerventional Products
  • Table 67: Terumo Corporation Neurovascular Product Portfolio SWOT Analysis, 2014
  • Table 68: MicroVention Neurovascular Intervention Marketed Products
  • Table 69: MicroVention Marketed Neurovascular Access Products
  • Table 70: MicroVention Neurovascular Product Portfolio SWOT Analysis, 2014
  • Table 71: Valor Medical Neurovascular Intervention Marketed Products
  • Table 72: Valor Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 73: Global Neurovascular Interventions Pipeline Products
  • Table 74: Aneurysm Occlusion Saddle SWOT Analysis, 2014
  • Table 75: EKOS EkoSonic SV System SWOT Analysis, 2014
  • Table 76: Flow-Diverting Thin-Film Nitinol Covered Stent SWOT Analysis, 2014
  • Table 77: Janjua Aneurysm Net SWOT Analysis, 2014
  • Table 78: Multilayer Aneurysm Repair System SWOT Analysis, 2014
  • Table 79: NAVIMAX SWOT Analysis, 2014
  • Table 80: Palmaz Scientific Stents SWOT Analysis, 2014
  • Table 81: Silk Road System SWOT Analysis, 2014
  • Table 82: BALT Extrusion Company Profile
  • Table 83: BALT Extrusion Neurovascular Intervention Marketed Products
  • Table 84: BALT Extrusion SWOT Analysis, 2014
  • Table 85: Covidien Company Profile
  • Table 86: Covidien Neurovascular Intervention Marketed Products
  • Table 87: Covidien SWOT Analysis, 2014
  • Table 88: Codman & Shurtleff Company Profile
  • Table 89: Codman & Shurtleff Neurovascular Intervention Marketed Products
  • Table 90: Codman & Shurtleff SWOT Analysis, 2014
  • Table 91: Cordis Corporation Company Profile
  • Table 92: Cordis Corporation Neurovascular Intervention Marketed Products
  • Table 93: Cordis Corporation SWOT Analysis, 2014
  • Table 94: Penumbra Company Profile
  • Table 95: Penumbra Neurovascular Intervention Marketed Products
  • Table 96: Penumbra SWOT Analysis, 2014
  • Table 97: Stryker Corporation Company Profile
  • Table 98: Stryker Corporation Neurovascular Intervention Marketed Products
  • Table 99: Stryker Corporation SWOT Analysis, 2014
  • Table 100: Terumo Corporation Company Profile
  • Table 101: Terumo Europe N.V. and Terumo Interventional Systems Neurovascular Intervention Marketed Products
  • Table 102: MicroVention Neurovascular Intervention Marketed Products
  • Table 103: Terumo Corporation SWOT Analysis, 2014
  • Table 104: Abbott Vascular Company Profile
  • Table 105: Abbott Vascular Neurovascular Intervention Marketed Products
  • Table 106: Abbott Vascular SWOT Analysis, 2014
  • Table 107: Boston Scientific Corporation Company Profile
  • Table 108: Boston Scientific Neurovascular Intervention Marketed Products
  • Table 109: Boston Scientific Corporation SWOT Analysis, 2014
  • Table 110: Cook Medical Company Profile
  • Table 111: Cook Medical Neurovascular Intervention Marketed Products
  • Table 112: Cook Medical SWOT Analysis, 2014
  • Table 113: Gore Medical Company Profile
  • Table 114: Gore Medical Neurovascular Intervention Marketed Products
  • Table 115: Gore Medical SWOT Analysis, 2014
  • Table 116: Medtronic Company Profile
  • Table 117: Medtronic Neurovascular Intervention Marketed Products
  • Table 118: Medtronic SWOT Analysis, 2014
  • Table 119: Aachen Resonance Company Profile
  • Table 120: Aachen Resonance Neurovascular Intervention Marketed Product
  • Table 121: Aachen Resonance SWOT Analysis, 2014
  • Table 122: Acandis Company Profile
  • Table 123: Acandis Neurovascular Intervention Marketed Products
  • Table 124: Acandis SWOT Analysis, 2014
  • Table 125: B. Braun Company Profile
  • Table 126: B. Braun Neurovascular Intervention Marketed Product
  • Table 127: B. Braun SWOT Analysis, 2014
  • Table 128: Blockade Medical Company Profile
  • Table 129: Blockade Medical Neurovascular Intervention Marketed Product
  • Table 130: Blockade Medical SWOT Analysis, 2014
  • Table 131: Contego Medical Company Profile
  • Table 132: Contego Medical Neurovascular Intervention Marketed Product
  • Table 133: Contego Medical SWOT Analysis, 2014
  • Table 134: Gardia Medical Company Profile
  • Table 135: Gardia Medical Neurovascular Intervention Marketed Product
  • Table 136: Gardia Medical SWOT Analysis, 2014
  • Table 137: InspireMD Company Profile
  • Table 138: InspireMD Neurovascular Intervention Marketed Product
  • Table 139: InspireMD SWOT Analysis, 2014
  • Table 140: ITGI Medical Company Profile
  • Table 141: ITGI Medical Neurovascular Intervention Marketed Product
  • Table 142: ITGI Medical SWOT Analysis, 2014
  • Table 143: Medikit Company Profile
  • Table 144: Medikit Neurovascular Intervention Marketed Products
  • Table 145: Medikit SWOT Analysis, 2014
  • Table 146: Merlin MD Company Profile
  • Table 147: Merlin MD Neurovascular Intervention Marketed Product
  • Table 148: Merlin MD SWOT Analysis, 2014
  • Table 149: MicroPort Scientific Corporation Company Profile
  • Table 150: MicroPort Scientific Corporation Neurovascular Intervention Marketed Products
  • Table 151: MicroPort Scientific Corporation SWOT Analysis, 2014
  • Table 152: Minvasys Company Profile
  • Table 153: Minvasys Neurovascular Intervention Marketed Product
  • Table 154: Minvasys SWOT Analysis, 2014
  • Table 155: Neuravi Company Profile
  • Table 156: Neuravi Neurovascular Intervention Marketed Product
  • Table 157: Neuravi SWOT Analysis, 2014
  • Table 158: Optimed Company Profile
  • Table 159: Optimed Neurovascular Intervention Marketed Products
  • Table 160: Optimed SWOT Analysis, 2014
  • Table 161: Phenox GmBH Company Profile
  • Table 162: Phenox GmbH Neurovascular Intervention Marketed Products
  • Table 163: Phenox GmBH SWOT Analysis, 2014
  • Table 164: Reverse Medical Company Profile
  • Table 165: Reverse Medical Neurovascular Intervention Marketed Products
  • Table 166: Reverse Medical SWOT Analysis, 2014
  • Table 167: Sequent Medical Company Profile
  • Table 168: Sequent Medical Neurovascular Intervention Marketed Products
  • Table 169: Sequent Medical SWOT Analysis, 2014
  • Table 170: Valor Medical Company Profile
  • Table 171: Valor Medical Neurovascular Intervention Marketed Products
  • Table 172: Valor Medical SWOT Analysis, 2014
  • Table 173: Other Companies in the Neurovascular Intervention Market, 2014
  • Table 174: Neurovascular Interventions Market Sales ($m) Forecast for the US, 2011-2020

List of Figures

  • Figure 1: Treatment Modalities - Neurovascular Interventions
  • Figure 2: Types of Stents Used for Neurovascular Interventions
  • Figure 3: Embolization Procedure Volume for Treating Intracranial Aneurysms, US, 2011-2020
  • Figure 4: Embolization Procedure Volume for Treating Intracranial Arteriovenous Malformations, US, 2011-2020
  • Figure 5: Revascularization Procedure Volume for Treating Atherosclerotic Disease, US, 2011-2020
  • Figure 6: Mechanical Thrombectomy Procedure Volume for Treating Acute Ischemic Stroke, US, 2011-2020
  • Figure 7: US Mean Hospital Costs* for Treating Intracranial Aneurysms and Arteriovenous Malformations, 2011-2020 ($US)
  • Figure 8: US Mean Hospital Costs* for Treating Extracranial and Intracranial Atherosclerotic Disease, 2011-2020 ($US)
  • Figure 9: US Mean Hospital Costs* for Treating Stroke, 2011-2020 ($US)
  • Figure 10: US Neurointerventional Market Distribution, 2013
  • Figure 11: Global Neurovascular Interventions Pipeline Products by Stage of Development, 2014
  • Figure 12: US Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 13: US Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 14: US Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 15: US Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 16: US Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
Back to Top